In sub-analyses of the mutant-type KRAS subgroup, PCR-based assays did not obviously change the therapeutics for CRC [HR 1.10, (95% CI, 0.99–1.23), P = 0.009] according to a fixed-effect model (P value for heterogeneity  = 0.42). This evidence concerns the gene KRAS and colorectal carcinoma.